Avapritinib
Avapritinib is a targeted therapy that blocks specific mutant proteins driving cancer cell growth. It is primarily used to treat adults with gastrointestinal stromal tumors (GIST) that have PDGFRA mutations, particularly the D842V mutation, when surgery is not an option or the cancer has spread.
Avapritinib is an oral tyrosine kinase inhibitor for treating certain GIST tumors with PDGFRA mutations.
Key facts at a glance
- ATC
- L01EX18
- RxNorm
- 2272107
- Generic
- Avapritinib
- Class
- atc-l01
- Brands
- Ayvakit
- Availability
- rx
- Lactation
- unknown
- Routes
- oral
- Forms
- tablet
- Regions
- US, EU, CN, JP
- Monitoring
- —
This page is for informational purposes only.
Do not use this information to diagnose yourself or to replace a physician's advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you believe you are experiencing a medical emergency, call your local emergency number immediately.
Dosage and administration
- Usual dose
- 500mg twice daily
- Maximum
- consult physician
- Frequency
- every 12 hours
- Instructions
- Follow physician instructions
- Duration limits
- as prescribed
- Monitoring
- standard
- Usual dose
- 250mg twice daily
- Maximum
- consult physician
- Frequency
- every 12 hours
- Instructions
- Follow physician instructions
- Duration limits
- as prescribed
- Monitoring
- standard
- Usual dose
- 400mg daily
- Maximum
- consult physician
- Frequency
- once daily
- Instructions
- Follow physician instructions
- Duration limits
- as prescribed
- Monitoring
- standard
Overdose information
Special Populations
10 groupspregnancy
first trimesteravoid if possible
avoid use during pregnancy unless benefits outweigh risks; women of childbearing potential should use effective contraception during treatment and for at least 6 weeks after last dose
regular fetal monitoring
Use of this medication in this population requires careful consideration of risks and benefits.
pregnancy
second trimesteravoid if possible
discontinue therapy if pregnancy occurs; consider risks versus benefits
regular fetal monitoring and ultrasound assessments
Use of this medication in this population requires careful consideration of risks and benefits.
pregnancy
third trimesteravoid if possible
avoid use near delivery; consider discontinuing therapy before third trimester if possible
fetal monitoring and assessment of fetal well-being
Use of this medication in this population requires careful consideration of risks and benefits.
lactation
breastfeedingnot recommended
do not breastfeed during treatment and for at least 4 weeks after last dose due to potential for serious adverse reactions in breastfed infants
monitor infant for adverse effects
Use of this medication in this population requires careful consideration of risks and benefits.
geriatric
elderly 65 and olderno specific adjustment required
monitor closely for adverse reactions; no dose adjustment needed based on age alone but start at lower end of dosing range
regular monitoring of renal and hepatic function; watch for adverse effects
Use with caution and monitor for adverse effects.
pediatric_age
children under 18not established
safety and efficacy not established in pediatric patients; use only in clinical trials or as per approved pediatric indication
limited data available; monitor growth and development if used
renal_impairment
mild to moderateno dose adjustment required
no dose adjustment needed for mild to moderate renal impairment; monitor renal function regularly
monitor renal function periodically
Use with caution and monitor for adverse effects.
renal_impairment
severereduce dose
use with caution in severe renal impairment; consider dose reduction and close monitoring
frequent monitoring of renal function and adverse effects
Use with caution and monitor for adverse effects.
hepatic_impairment
mildno dose adjustment required
no dose adjustment needed for mild hepatic impairment
monitor hepatic function periodically
Use with caution and monitor for adverse effects.
hepatic_impairment
moderate to severereduce dose
reduce starting dose for moderate to severe hepatic impairment; use with caution and monitor closely
frequent monitoring of liver function tests and adverse effects
Use of this medication in this population requires careful consideration of risks and benefits.
Statistics and clinical data
FDA approval year
FDA approval for treatment of PDGFRA exon 18 mutated gastrointestinal stromal tumors (GIST)
Drug class
Molecular mechanism of action classification
Primary indication
Therapeutic indication for Avvakit
Primary target
Molecular target of the drug
Treats adults with unresectable or metastatic gastrointestinal stromal tumors (GIST) containing PDGFRA exon 18 mutations, including the D842V mutation.
Blocks the activity of mutant PDGFRA and KIT proteins, which are abnormally active forms of receptors that promote cancer cell growth and survival.
Requires genetic testing to confirm PDGFRA mutation status before treatment. Common side effects may include cognitive effects, fatigue, and fluid retention. Should be prescribed by a specialist experienced in oncology.
Contraindications
Conditions and patient states where this medication should be avoided or used with caution.
Do not use (1)
Known allergy to this medication or its components
Use caution (1)
Consult healthcare provider for benefits vs risks assessment
Official drug label
WellAlly may earn a referral fee from linked resources at no extra cost to you. Editorial content is never influenced by commercial relationships.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed July 26, 2026. · Read our editorial policy